This company has been marked as potentially delisted and may not be actively trading. Cleveland BioLabs (CBLI) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CBLI vs. SCPS, VAXX, EVLO, CMRA, ARDS, STAB, CLVR, EFTR, MTEM, and ONCSQShould you be buying Cleveland BioLabs stock or one of its competitors? The main competitors of Cleveland BioLabs include Scopus BioPharma (SCPS), Vaxxinity (VAXX), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Clever Leaves (CLVR), eFFECTOR Therapeutics (EFTR), Molecular Templates (MTEM), and OncoSec Medical (ONCSQ). These companies are all part of the "medical" sector. Cleveland BioLabs vs. Its Competitors Scopus BioPharma Vaxxinity Evelo Biosciences Comera Life Sciences Aridis Pharmaceuticals Statera Biopharma Clever Leaves eFFECTOR Therapeutics Molecular Templates OncoSec Medical Cleveland BioLabs (NASDAQ:CBLI) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations. Which has better earnings & valuation, CBLI or SCPS? Cleveland BioLabs has higher revenue and earnings than Scopus BioPharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCleveland BioLabs$260K0.00-$2.40MN/AN/AScopus BioPharmaN/AN/A-$11.61MN/AN/A Do insiders and institutionals believe in CBLI or SCPS? 5.1% of Cleveland BioLabs shares are owned by institutional investors. 1.0% of Cleveland BioLabs shares are owned by insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media favor CBLI or SCPS? In the previous week, Scopus BioPharma had 2 more articles in the media than Cleveland BioLabs. MarketBeat recorded 2 mentions for Scopus BioPharma and 0 mentions for Cleveland BioLabs. Cleveland BioLabs' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score. Company Overall Sentiment Cleveland BioLabs Neutral Scopus BioPharma Neutral Is CBLI or SCPS more profitable? Scopus BioPharma's return on equity of 0.00% beat Cleveland BioLabs' return on equity.Company Net Margins Return on Equity Return on Assets Cleveland BioLabsN/A -32.84% -31.29% Scopus BioPharma N/A N/A N/A Which has more volatility and risk, CBLI or SCPS? Cleveland BioLabs has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.24, meaning that its stock price is 124% less volatile than the S&P 500. SummaryCleveland BioLabs and Scopus BioPharma tied by winning 4 of the 8 factors compared between the two stocks. Get Cleveland BioLabs News Delivered to You Automatically Sign up to receive the latest news and ratings for CBLI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CBLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CBLI vs. The Competition Export to ExcelMetricCleveland BioLabsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$5K$782.11M$5.54B$8.87BDividend YieldN/A4.84%5.39%4.10%P/E RatioN/A1.0926.1619.90Price / SalesN/A219.25413.33113.66Price / CashN/A23.4436.1356.90Price / BookN/A5.998.055.38Net Income-$2.40M-$27.64M$3.15B$248.50M Cleveland BioLabs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CBLICleveland BioLabsN/AN/AN/AN/A$5K$260K0.004News CoverageEarnings ReportSCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009Gap DownVAXXVaxxinityN/A$0.00flatN/A-100.0%$13KN/A0.0090EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120Upcoming EarningsCMRAComera Life SciencesN/A$0.00flatN/A-99.2%$6K$1.00M0.002ARDSAridis PharmaceuticalsN/A$0.00flatN/A-99.9%$5K$3.09M0.0030STABStatera BiopharmaN/A$0.00flatN/A-83.3%$5KN/A0.0020CLVRClever LeavesN/A$0.00flatN/A-100.0%$1K$17.42M0.00560EFTReFFECTOR TherapeuticsN/A$0.00flatN/A-99.8%$1K$3.55M0.0010Gap DownMTEMMolecular TemplatesN/AN/AN/AN/A$1K$23.48M0.00260ONCSQOncoSec MedicalN/AN/AN/AN/A$1KN/A0.0040 Related Companies and Tools Related Companies Scopus BioPharma Alternatives Vaxxinity Alternatives Evelo Biosciences Alternatives Comera Life Sciences Alternatives Aridis Pharmaceuticals Alternatives Statera Biopharma Alternatives Clever Leaves Alternatives eFFECTOR Therapeutics Alternatives Molecular Templates Alternatives OncoSec Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CBLI) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cleveland BioLabs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cleveland BioLabs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
